An early-stage medical tech startup receives $250,000 in seed funding from an angel investor, who plans to triple the investment in five years with 20% annual compound interest. How much will the investment be worth at that time?

How An Early-Stage Medical Tech Startup’s Seed Funding Is Growing with Compound Interest

In a growing number of U.S. markets, seed funding is reshaping how early-stage medical tech startups gain momentum. One compelling example: a promising medical technology startup that recently secured $250,000 in seed capital from an angel investor—funds earmarked to accelerate product development, clinical validation, and market entry. With a clear vision to deliver scalable health innovations, this company’s investment trajectory highlights both the power of patient capital and the predictable growth expected in high-impact healthcare innovation.

Why is this funding round attracting attention? The medical tech sector is experiencing unprecedented momentum, driven by rising demand for digital health solutions, aging populations, and advances in data-driven diagnostics and treatment platforms. Angel investors increasingly target such early-stage ventures not just for financial return, but for the potential to accelerate life-improving technologies into real-world use faster than traditional funding channels allow.

Understanding the Context

Now, the core calculation: the investor plans to triple the initial $250,000 over five years using 20% annual compound interest. This 20% rate—common in growth-focused early-stage investments—reflects both market confidence and the startup’s strategic use of capital. With compounding, the investment grows in steps, multiplicating returns as interest compounds each year.